Report : North America Generic Injectables Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Large Molecule Injectables and Small Molecule Injectables), Container Type (Vials, Premix, Prefilled Syringes, Ampoules, and Others), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others), and Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others)
Large Molecule Injectables Segment to Dominate North America Generic Injectables Market during 2019–2028
According to a new market research study on “North America Generic Injectables Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Container Type, Application, and Route of Administration,” is expected to reach US$ 45,208.73 million by 2028 from US$ 22,072.74 million in 2021. The market is estimated to grow at a CAGR of 10.8% from 2021 to 2028. Low R&D, marketing, and manufacturing costs is the major factor driving the growth of the North America generic injectables market. However, critical inspection system for prefilled injection may hinder the growth of North America generic injectables market. The report provides trends prevailing in the North America generic injectables market along with the drivers and restraints pertaining to the market growth.
The North America generic injectables market is segmented into product type, container type, application, route of administration, and country. The North America generic injectables market, based on product type, has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held the largest share North America generic injectables market. The North America generic injectables market, based on container type, has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share North America generic injectables market. The North America generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share North America generic injectables market. The North America generic injectables market, based on route of administration, has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest share North America generic injectables market. Similarly, based on country, the North America generic injectables market is segmented into the US, Canada, and Mexico. The US contributed a substantial share in 2020.
AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Pfizer Inc.; and Viatris Inc are among the leading companies in the North America generic injectables market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Baxter announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix Injections and Clinimix E Injections. The introduction of Clinimix and Clinimix E formulations offers the highest protein in a multi-chamber bag in the U.S., allowing clinicians more flexibility in meeting their patients' nutritional goals.
North America Generic Injectables Market, By Country, 2020 and 2028 (%)
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com